Improvements in Medical Therapy and Prognosis for Patients with HFrEF Following the 2021 ESC HF Guidelines
The utilisation of GDMT in Norwegian HF clinics has increased markedly since 2016, with a fourfold acceleration in MRA and a substantial increase in SGLT2i use following the 2021 ESC HF guidelines. HF hospitalisations have consistently declined, while mortality rates first declined after 2021.
Authors
- Tone M Norekvål (ORCID: https://orcid.org/0000-0003-3640-2119)
- Kristian Berge (ORCID: https://orcid.org/0000-0002-4494-376X)
- Lars Gullestad (ORCID: https://orcid.org/0000-0002-5932-6641)
- Hamza Nahoui
- Henrik Schirmer (ORCID: https://orcid.org/0000-0002-9348-3149)
- Stein Ørn (ORCID: https://orcid.org/0000-0002-5098-4592)
- Kristina Larsby
- Tarjei Øvrebotten (ORCID: https://orcid.org/0000-0002-5335-7754)
- Peder Langeland Myhre (ORCID: https://orcid.org/0000-0002-5871-1804)
- Torstein Hole (ORCID: https://orcid.org/0000-0001-5225-8482)
- Charlotte Björk Ingul
- Torbjørn Omland
- Rune Mo (ORCID: https://orcid.org/0000-0003-3647-4796)
Institutions
- Oslo University Hospital (NO)
- University Hospital of North Norway (NO)
- University of Oslo (NO)
- Norwegian University of Science and Technology (NO)
- Stavanger University Hospital (NO)
- Akershus University Hospital (NO)
- Haukeland University Hospital (NO)
- Ålesund Hospital (NO)
- St Olav's University Hospital (NO)
- University of Bergen (NO)
- University of Stavanger (NO)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1002/ehf2.15337
- Citations
- 2
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Helse Sør-Øst RHF